Treatment response assessment in transthyretin-related cardiac amyloidosis: an emerging clinical indication of bone-seeking radiopharmaceuticals?
(2024) European Journal of Nuclear Medicine and Molecular Imaging — Vol. 51, n° 3, p. 691-694 (2024)
Files
2024_Gheysens_Eur_J_Nucl_Med_Mol_Imaging.pdf
Open Access - Adobe PDF
- 480.64 KB
Details
- Authors
- Abstract
- Transthyretin amyloid cardiomyopathy (ATTR-CM) is a severe and progressive restrictive infiltrative cardiomyopathy caused by the deposition of misfolded amyloid fibrils in the myocardium. Cardiac SPECT or SPECT/CT using 99mTc-radiolabeled bone-seeking radiopharmaceuticals complements echocardiography and cardiac magnetic resonance and has revolutionized the management of patients with suspected ATTR-CM. In particular, cardiac SPECT with bone-seeking radiopharmaceuticals allows to obtain a non-biopsy diagnosis of ATTR-CM with high accuracy if a plasma cell dyscrasia is excluded according to current international guidelines. [...]
- Affiliations
Citations
Gheysens, O., Treglia, G., Masri, A., Hyafil, F., & Dorbala, S. (2024). Treatment response assessment in transthyretin-related cardiac amyloidosis: an emerging clinical indication of bone-seeking radiopharmaceuticals? European Journal of Nuclear Medicine and Molecular Imaging, 51(3), 691-694. https://doi.org/10.1007/s00259-023-06576-8 (Original work published 2024)